Stahl Neil
- SEC CIK
- 0001226689
No open-market purchases or sales filed in the past year.
Current role at each company
- REGN Regeneron Pharmaceuticals, Inc.EVP Research and Developmentas of Dec 18, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Stahl Neil as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2024 (view filing) | Aug 8 | 4 days | Stahl NeilEVP Research and Development | SSale | −5.20K | $1,084.54 | −$5.64M | −9.2%51.0K after | 6 lots10b5-1 |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Stahl NeilEVP Research and Development | SSale | −8.04K | $950.35 | −$7.64M | −13.4%52.0K after | 7 lots |
| Aug 23, 2023 (view filing) | Aug 22 | 1 day | Stahl NeilEVP Research and Development | SSale | −11.7K | $840.98 | −$9.81M | −18.0%53.1K after | 3 lots |
| Aug 8, 2022 (view filing) | Aug 5 | 3 days | Stahl NeilEVP Research and Development | SSale | −23.8K | $612.61 | −$14.6M | −31.1%52.8K after | 16 lots |